The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer
Kerstin Borgmann, Annette Raabe, Sebastian Reuther, Silke Szymczak, Thorsten Schlomm, Hendrik Isbarn, Maria Gomolka, Andreas Busjahn, Michael Bonin, Andreas Ziegler, Ekkehard Dikomey
Radiotherapy and Oncology 96 (2010) 19-24
Purpose: Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors.
Materials and methods: The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay.
Results: No difference between healthy donors and prostate cancer patients was detected concerning G0- radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18 to -0.08, p = 0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p = 1.75-9). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%.
Conclusion: G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.
Heritability of left ventricular and papillary muscle heart size: a twin study with cardiac magnetic resonance imaging
Busjahn CA, Schulz-Menger J, Abdel-Aty H, Rudolph A, Jordan J, Luft FC, Busjahn A
Eur Heart J. 2009 Apr 30. [Epub ahead of print]
Aims Earlier studies in monozygotic (MZ) and dizygotic (DZ) twins showed genetic variance on echocardiographically determined heart size. However, cardiovascular magnetic resonance (CMR) is more precise and reproducible. We performed a twin study relying on CMR, focusing on left ventricular (LV) mass and papillary muscle, since there are no genetic reports on this structure. Methods and results We measured left heart dimensions of 25 healthy twin pairs with a 1.5T MR scanner, analysed with the mass(c), Medis Software. We performed heritability analysis and tests for genetic influences shared between cardiac structures. We found that CMR-based heritability estimates (h(2) = 84%) substantially exceeded estimates based on echocardiography. We also found significant genetic influence on papillary muscle mass (h(2) = 82%). Bivariate analysis of papillary and LV muscle mass revealed significant genetic influences shared by both phenotypes (genetic correlation 0.59) and suggested an additional genetic component specific to papillary muscle. We observed correlations between body mass index, surface area, and systolic blood pressure with cardiac dimensions, even in this small study. Environmental influences were relevant as well, indicating reciprocal influences on papillary vs. LV muscle mass. Conclusion Cardiovascular magnetic resonance, even with few subjects, allows a genetic assessment of cardiac structures that cannot be attained with echocardiography. Hitherto fore unappreciated relationships can be uncovered by this method.
Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins
Tania Perrinjaquet-Moccetti, Andreas Busjahn, Caesar Schmidlin, Annette Schmidt, Barbara Bradl, Cem Aydogan
Phytotherapy Research Volume 22 Issue 9, Pages 1239 - 1242
Hypertension is a harmful disease factor that develops unnoticed over time. The treatment of hypertension is aimed at an early diagnosis followed by adequate lifestyle changes rather than pharmacological treatment. The olive leaf extract EFLA943, having antihypertensive actions in rats, was tested as a food supplement in an open study including 40 borderline hypertensive monozygotic twins. Twins of each pair were assigned to different groups receiving 500 or 1000 mg/day EFLA943 for 8 weeks, or advice on a favourable lifestyle. Body weight, heart rate, blood pressure, glucose and lipids were measured fortnightly. Blood pressure changed significantly within pairs, depending on the dose, with mean systolic differences of 6 mmHg (500 mg vs control) and 13 mmHg (1000 vs 500 mg), and diastolic differences of 5 mmHg. After 8 weeks, mean blood pressure remained unchanged from baseline in controls (systolic/diastolic: 133 5/77 6 vs 135 11/80 7 mmHg) and the low-dose group (136 7/77 7 vs 133 10/76 7), but had significantly decreased for the high dose group (137 10/80 10 vs 126 9/76 6). Cholesterol levels decreased for all treatments with significant dose-dependent within-pair differences for LDL-cholesterol. None of the other parameters showed significant changes or consistent trends. Concluding, the study confirmed the antihypertensive and cholesterol-lowering action of EFLA943 in humans.